Cardiff Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cardiff Oncology, Inc. (CRDF) on April 2, 2026, covering events occurring on March 27, 2026. The filing details the formal separation of the company's former Chief Executive Officer, Dr. Mark Erlander, and Chief Financial Officer, James Levine, following a strategic review announced in January 2026.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and separation terms.
Material Changes and Executive Separation
On March 27, 2026, the Company entered into separation agreements with Dr. Erlander and Mr. Levine. Key terms include:
- Dr. Mark Erlander (Former CEO):
- Base salary of $635,000 paid over 12 months.
- 2025 bonus of $122,238.
- 50% of the 2026 target bonus, pro-rated over 12 months.
- Healthcare benefits for up to 12 months.
- Stock options continue vesting until June 2026; vested options exercisable for 12 months thereafter.
- Entered into a consulting agreement with the Company.
- Resigned from the Board of Directors.
- James Levine (Former CFO):
- Base salary of $490,000 paid over 12 months.
- 2025 bonus of $61,740.
- 50% of the 2026 target bonus, pro-rated over 12 months.
- Healthcare benefits for up to 12 months.
- Vested stock options exercisable for 12 months after the Separation Date.
Both executives agreed to a general release and confidentiality provisions.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlook, or specific risk factors beyond the operational impact of the leadership transition. The departure of the CEO and CFO represents a significant management change that may impact strategic execution.
Investor Verification Checklist
- Verify the appointment of interim or permanent replacements for the CEO and CFO roles.
- Review the terms of the consulting agreement entered into with Dr. Erlander.
- Assess the impact of the $1.3 million+ in immediate and deferred compensation obligations on the company's cash position.
- Confirm the status of the strategic review mentioned in the January 2026 disclosure.